Oph­thalmic biotech rais­es $16.5M; Pfiz­er’s AI col­lab­o­ra­tion bears fruit

Plus, news about Biodexa Phar­ma­ceu­ti­cals:

RevOp­sis Ther­a­peu­tics se­cures $16.5M seed round: The San Car­los, CA-based biotech will use the funds to com­plete IND-en­abling stud­ies for its lead can­di­date, RO-104, for neo­vas­cu­lar age-re­lat­ed mac­u­lar de­gen­er­a­tion and hire key man­age­ment staff. First-in-hu­man stud­ies of RO-104 are ex­pect­ed to start in 2025, the com­pa­ny said.

Pfiz­er and CeMM tout AI plat­form: Pfiz­er worked with the Aus­tri­an re­search cen­ter, CeMM Forschungszen­trum für Moleku­lare Medi­zin, to scale a plat­form that en­ables them to mea­sure “how hun­dreds of small mol­e­cules with var­i­ous chem­i­cal struc­tures in­ter­act with all ex­pressed pro­teins in liv­ing cells.” The process has led to a cat­a­log of tens of thou­sands of lig­and-pro­tein in­ter­ac­tions that can now be used for drug dis­cov­ery pur­pos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER